Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment–Elevation Myocardial Infarction
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background—: Liraglutide, a glucagon-like peptide-1 analog, was reported to reduce reperfusion injury in mice. We planned to evaluate the effects of liraglutide on reperfusion injury in patients with acute ST-segment–elevation myocardial infarction treated with primary percutaneous coronary intervention. Methods and Results—: A total of 96 patients with ST-segment–elevation myocardial infarction undergoing emergency primary percutaneous coronary intervention were randomized to receive either subcutaneous liraglutide or placebo. Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days). The salvage index was calculated from myocardial area at risk, measured during the index admission (35±12 hours), and final infarct size measured at 91±5 days after primary percutaneous coronary intervention by cardiac magnetic resonance. At 3 months, the primary end point, a higher salvage index was found in the liraglutide group than in the placebo group in 77 patients evaluated with cardiac magnetic resonance (0.66±0.14 versus 0.55±0.15; P =0.001). The final infarct size was lower in the liraglutide group than that in the placebo group (15±12 versus 21±15 g; P =0.05). Serum high-sensitivity C-reactive protein level was lower in the liraglutide group ( P <0.001). During a 6-month follow-up period, no difference was observed in the incidence of major adverse cardiovascular event. Safety and tolerability were similar among the 2 groups. Conclusions—: Our study provides evidence that liraglutide improves myocardial salvage and infarct size after ST-segment–elevation myocardial infarction, possibly by reducing reperfusion injury, making it a promising treatment for evaluation in larger trials. Clinical Trial Registration—: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02001363.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · cited 1×
“GLP-1 can ameliorate endothelial dysfunction.(39) In this study, the NO and NO synthase levels in the liraglutide group were significantly higher than those in the control group, and the administration of liraglutide led to a reduction in serum ET-1 levels.”
BackgroundRetractedYellon, D. M., & Hausenloy, D. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071667 · Cited by 3,797
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“Liraglutide, a GLP-1 analog, was reported to reduce infarct size and improve cardiac output in normal and diabetic mice.(8) Several studies have shown that exenatide (another GLP-1 analog) protects against ischemia-reperfusion injury and reduces infarct size in patients with STEMI.”
BackgroundCeriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204
Cited by
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Jin, Q., Li, R., Hu, N., Xin, T., Zhu, P., Hu, S., Ma, S., Zhu, H., Ren, J., & Zhou, H. (2018) · Redox Biology · doi:10.1016/j.redox.2017.11.004 · Cited by 463
Self-citationZhou, H., Wang, J., Zhu, P., Zhu, H., Toan, S., Hu, S., Ren, J., & Chen, Y. (2018) · Basic Research in Cardiology · doi:10.1007/s00395-018-0682-1 · Cited by 297
Self-citationRetractedSposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Heuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106
Metadata
- Authors
- Chen, W. R., Chen, Y. D., Tian, F., Yang, N., Cheng, L. Q., Hu, S. Y., Wang, J., Yang, J. J., Wang, S. F., & Gu, X. F.
- Venue
- Circulation: Cardiovascular Imaging
- Published
- 2016-12
- Volume
- 9
- Issue
- 12
- ISSN
- 1941-9651 (ISSN-L)
- 1942-0080
- OpenAlex
- W2560522494
- Cited by
- 100
- References
- 5
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment–Elevation Myocardial Infarction. https://app.cochat.ai/papers/10.1161/circimaging.116.005146
- The paper
- Chen, W. R., Chen, Y. D., Tian, F., Yang, N., Cheng, L. Q., Hu, S. Y., Wang, J., Yang, J. J., Wang, S. F., & Gu, X. F. (2016). Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging. https://doi.org/10.1161/circimaging.116.005146
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.